Subconjunctival Palomid 529 in the treatment of neovascular age-related macular degeneration

Monica Dalal, Naima Jacobs-El, Benjamin Nicholson, Jingsheng Tuo, Emily Chew, Chi Chao Chan, Robert Nussenblatt, Frederick Ferris, Catherine Meyerle

Research output: Contribution to journalArticle

Abstract

Background: Recent evidence suggests that neovascular age-related macular degeneration (AMD) may have an immune mediated component. Palomid 529, an investigational medication involving the immune Akt/mTOR pathway, is unique in dissociating both targets of rapamycin complexes TORC1 and TORC2. This small short-term pilot study assesses the safety of subconjunctival Palomid 529 in the treatment of neovascular AMD, with some limited efficacy information. Methods: In this 12-week phase I open-label prospective pilot study, five participants with neovascular age-related macular degeneration that were refractory to intravitreal anti-vascular endothelial growth factor (VEGF) received three serial monthly subconjunctival doses of 1.9 mg Palomid 529. All participants were also offered concomitant monthly intravitreal anti-VEGF injections. Safety was monitored via adverse events recording. Additional outcome measures included visual acuity, optical coherence tomography, fluorescein angiography, indocyanine green angiography and fundus photography. Results: The study drug was well-tolerated by all participants. There were no drug-related adverse events and no serious adverse events. A depot formed at the injection site, which persisted at the end of the study. In these anti-VEGF refractory patients, no clinically important changes in best-corrected visual acuity, fluorescein leakage pattern, choroidal neovascularization size on indocyanine green angiography, or autofluorescence pattern on fundus autofluorescence were observed compared to baseline. The fluid status, assessed with optical coherence tomography showed that central retinal thickness and macular volume remained stable in three participants, while the other two participants clinically progressed. Conclusions: Serial subconjunctival injections of Palomid 529 were well-tolerated and resulted in depot formation. There were no concerns for any ocular or systemic toxicity during this small short-term study. Larger randomized studies are required to determine efficacy.

Original languageEnglish (US)
Pages (from-to)2705-2709
Number of pages5
JournalGraefe's Archive for Clinical and Experimental Ophthalmology
Volume251
Issue number12
DOIs
StatePublished - Dec 2013
Externally publishedYes

Fingerprint

Macular Degeneration
Vascular Endothelial Growth Factor A
Indocyanine Green
Optical Coherence Tomography
Injections
Visual Acuity
Angiography
Safety
Choroidal Neovascularization
Fluorescein Angiography
Photography
Sirolimus
Therapeutics
Drug-Related Side Effects and Adverse Reactions
Fluorescein
Outcome Assessment (Health Care)
Prospective Studies
palomid 529
Pharmaceutical Preparations

Keywords

  • Akt/mTOR
  • Choroidal neovascularization
  • Neovascular age-related macular degeneration
  • Palomid 529

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Subconjunctival Palomid 529 in the treatment of neovascular age-related macular degeneration. / Dalal, Monica; Jacobs-El, Naima; Nicholson, Benjamin; Tuo, Jingsheng; Chew, Emily; Chan, Chi Chao; Nussenblatt, Robert; Ferris, Frederick; Meyerle, Catherine.

In: Graefe's Archive for Clinical and Experimental Ophthalmology, Vol. 251, No. 12, 12.2013, p. 2705-2709.

Research output: Contribution to journalArticle

Dalal, M, Jacobs-El, N, Nicholson, B, Tuo, J, Chew, E, Chan, CC, Nussenblatt, R, Ferris, F & Meyerle, C 2013, 'Subconjunctival Palomid 529 in the treatment of neovascular age-related macular degeneration', Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 251, no. 12, pp. 2705-2709. https://doi.org/10.1007/s00417-013-2375-7
Dalal, Monica ; Jacobs-El, Naima ; Nicholson, Benjamin ; Tuo, Jingsheng ; Chew, Emily ; Chan, Chi Chao ; Nussenblatt, Robert ; Ferris, Frederick ; Meyerle, Catherine. / Subconjunctival Palomid 529 in the treatment of neovascular age-related macular degeneration. In: Graefe's Archive for Clinical and Experimental Ophthalmology. 2013 ; Vol. 251, No. 12. pp. 2705-2709.
@article{88411911ca994ed1b68ebe6409e01a9e,
title = "Subconjunctival Palomid 529 in the treatment of neovascular age-related macular degeneration",
abstract = "Background: Recent evidence suggests that neovascular age-related macular degeneration (AMD) may have an immune mediated component. Palomid 529, an investigational medication involving the immune Akt/mTOR pathway, is unique in dissociating both targets of rapamycin complexes TORC1 and TORC2. This small short-term pilot study assesses the safety of subconjunctival Palomid 529 in the treatment of neovascular AMD, with some limited efficacy information. Methods: In this 12-week phase I open-label prospective pilot study, five participants with neovascular age-related macular degeneration that were refractory to intravitreal anti-vascular endothelial growth factor (VEGF) received three serial monthly subconjunctival doses of 1.9 mg Palomid 529. All participants were also offered concomitant monthly intravitreal anti-VEGF injections. Safety was monitored via adverse events recording. Additional outcome measures included visual acuity, optical coherence tomography, fluorescein angiography, indocyanine green angiography and fundus photography. Results: The study drug was well-tolerated by all participants. There were no drug-related adverse events and no serious adverse events. A depot formed at the injection site, which persisted at the end of the study. In these anti-VEGF refractory patients, no clinically important changes in best-corrected visual acuity, fluorescein leakage pattern, choroidal neovascularization size on indocyanine green angiography, or autofluorescence pattern on fundus autofluorescence were observed compared to baseline. The fluid status, assessed with optical coherence tomography showed that central retinal thickness and macular volume remained stable in three participants, while the other two participants clinically progressed. Conclusions: Serial subconjunctival injections of Palomid 529 were well-tolerated and resulted in depot formation. There were no concerns for any ocular or systemic toxicity during this small short-term study. Larger randomized studies are required to determine efficacy.",
keywords = "Akt/mTOR, Choroidal neovascularization, Neovascular age-related macular degeneration, Palomid 529",
author = "Monica Dalal and Naima Jacobs-El and Benjamin Nicholson and Jingsheng Tuo and Emily Chew and Chan, {Chi Chao} and Robert Nussenblatt and Frederick Ferris and Catherine Meyerle",
year = "2013",
month = "12",
doi = "10.1007/s00417-013-2375-7",
language = "English (US)",
volume = "251",
pages = "2705--2709",
journal = "Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie",
issn = "0721-832X",
publisher = "Springer Verlag",
number = "12",

}

TY - JOUR

T1 - Subconjunctival Palomid 529 in the treatment of neovascular age-related macular degeneration

AU - Dalal, Monica

AU - Jacobs-El, Naima

AU - Nicholson, Benjamin

AU - Tuo, Jingsheng

AU - Chew, Emily

AU - Chan, Chi Chao

AU - Nussenblatt, Robert

AU - Ferris, Frederick

AU - Meyerle, Catherine

PY - 2013/12

Y1 - 2013/12

N2 - Background: Recent evidence suggests that neovascular age-related macular degeneration (AMD) may have an immune mediated component. Palomid 529, an investigational medication involving the immune Akt/mTOR pathway, is unique in dissociating both targets of rapamycin complexes TORC1 and TORC2. This small short-term pilot study assesses the safety of subconjunctival Palomid 529 in the treatment of neovascular AMD, with some limited efficacy information. Methods: In this 12-week phase I open-label prospective pilot study, five participants with neovascular age-related macular degeneration that were refractory to intravitreal anti-vascular endothelial growth factor (VEGF) received three serial monthly subconjunctival doses of 1.9 mg Palomid 529. All participants were also offered concomitant monthly intravitreal anti-VEGF injections. Safety was monitored via adverse events recording. Additional outcome measures included visual acuity, optical coherence tomography, fluorescein angiography, indocyanine green angiography and fundus photography. Results: The study drug was well-tolerated by all participants. There were no drug-related adverse events and no serious adverse events. A depot formed at the injection site, which persisted at the end of the study. In these anti-VEGF refractory patients, no clinically important changes in best-corrected visual acuity, fluorescein leakage pattern, choroidal neovascularization size on indocyanine green angiography, or autofluorescence pattern on fundus autofluorescence were observed compared to baseline. The fluid status, assessed with optical coherence tomography showed that central retinal thickness and macular volume remained stable in three participants, while the other two participants clinically progressed. Conclusions: Serial subconjunctival injections of Palomid 529 were well-tolerated and resulted in depot formation. There were no concerns for any ocular or systemic toxicity during this small short-term study. Larger randomized studies are required to determine efficacy.

AB - Background: Recent evidence suggests that neovascular age-related macular degeneration (AMD) may have an immune mediated component. Palomid 529, an investigational medication involving the immune Akt/mTOR pathway, is unique in dissociating both targets of rapamycin complexes TORC1 and TORC2. This small short-term pilot study assesses the safety of subconjunctival Palomid 529 in the treatment of neovascular AMD, with some limited efficacy information. Methods: In this 12-week phase I open-label prospective pilot study, five participants with neovascular age-related macular degeneration that were refractory to intravitreal anti-vascular endothelial growth factor (VEGF) received three serial monthly subconjunctival doses of 1.9 mg Palomid 529. All participants were also offered concomitant monthly intravitreal anti-VEGF injections. Safety was monitored via adverse events recording. Additional outcome measures included visual acuity, optical coherence tomography, fluorescein angiography, indocyanine green angiography and fundus photography. Results: The study drug was well-tolerated by all participants. There were no drug-related adverse events and no serious adverse events. A depot formed at the injection site, which persisted at the end of the study. In these anti-VEGF refractory patients, no clinically important changes in best-corrected visual acuity, fluorescein leakage pattern, choroidal neovascularization size on indocyanine green angiography, or autofluorescence pattern on fundus autofluorescence were observed compared to baseline. The fluid status, assessed with optical coherence tomography showed that central retinal thickness and macular volume remained stable in three participants, while the other two participants clinically progressed. Conclusions: Serial subconjunctival injections of Palomid 529 were well-tolerated and resulted in depot formation. There were no concerns for any ocular or systemic toxicity during this small short-term study. Larger randomized studies are required to determine efficacy.

KW - Akt/mTOR

KW - Choroidal neovascularization

KW - Neovascular age-related macular degeneration

KW - Palomid 529

UR - http://www.scopus.com/inward/record.url?scp=84891383442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891383442&partnerID=8YFLogxK

U2 - 10.1007/s00417-013-2375-7

DO - 10.1007/s00417-013-2375-7

M3 - Article

C2 - 23689994

AN - SCOPUS:84891383442

VL - 251

SP - 2705

EP - 2709

JO - Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie

JF - Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie

SN - 0721-832X

IS - 12

ER -